^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Jingzhuda (entinostat) (HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 1555: Single cell level treatment-specific characterization of HER2+ breast cancers treated with immune checkpoint inhibitors and entinostat
Published date:
05/15/2020
Excerpt:
Our results showed that entinostat in combination with anti-PD-1, anti-CTLA-4, or both provided a significant survival benefit compared to either treatment alone.
DOI:
10.1158/1538-7445.AM2020-1555
